<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37024264</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2796</ISSN><JournalIssue CitedMedium="Internet"><Volume>293</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of internal medicine</Title><ISOAbbreviation>J Intern Med</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 antibody dynamics over time and risk factors associated with infection and long COVID-19 symptoms in large working environments.</ArticleTitle><Pagination><StartPage>763</StartPage><EndPage>781</EndPage><MedlinePgn>763-781</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/joim.13637</ELocationID><Abstract><AbstractText Label="BACKGROUND">Factors influencing SARS-CoV-2 antibody dynamics, transmission, waning and long COVID-19 symptomatology are still not fully understood.</AbstractText><AbstractText Label="METHODS">In the Danish section of the Novo Nordisk Group, we performed a prospective seroepidemiological study during the first and second waves of the COVID-19 pandemic. All employees and their household members (&gt;18 years) were invited to participate in a baseline (June-August 2020), 6-month follow-up (December 2020-January 2021), and 12-month follow-up (August 2021) sampling. In total, 18,614 accepted and provided at least one blood sample and completed a questionnaire regarding socioeconomic background, health status, previous SARS-CoV-2 infection, and persistent symptoms. Total antibody and specific IgM, IgG and IgA levels against recombinant receptor binding domain were tested.</AbstractText><AbstractText Label="RESULTS">At baseline, the SARS-CoV-2-antibody seroprevalence was 3.9%. At 6-month follow-up, the seroprevalence was 9.1%, while at 12-month follow-up, the seroprevalence was 94.4% (after the vaccine roll-out). Male sex and younger age (18-40 years) were significant risk factors for seropositivity. From baseline to the 6-month sampling, we observed a substantial waning of IgM, IgG and IgA levels (p&#xa0;&lt;&#xa0;0.001), regardless of age, sex and initial antibody level. An increased antibody level was found in individuals infected prior to vaccination compared to vaccinated infection na&#xef;ves (p&#xa0;&lt;&#xa0;0.0001). Approximately a third of the seropositive individuals reported one or more persistent COVID-19 symptoms, with anosmia and/or ageusia (17.5%) and fatigue (15.3%) being the most prevalent.</AbstractText><AbstractText Label="CONCLUSION">The study provides a comprehensive insight into SARS-CoV-2 antibody seroprevalence following infection and vaccination, waning, persistent COVID-19 symptomatology and risk factors for seropositivity in large working environments.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Journal of Internal Medicine published by John Wiley &amp; Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Cecilie Bo</ForeName><Initials>CB</Initials><Identifier Source="ORCID">0000-0002-7709-4522</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dvoncova</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Al&#xf3;s</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fogh</LastName><ForeName>Kamille</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine and Cardiology, Herlev and Gentofte Hospital, Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madsen</LastName><ForeName>Johannes Roth</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0003-3083-5992</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garred</LastName><ForeName>Caroline Hartwell</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jarlhelt</LastName><ForeName>Ida</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Pernille Brok</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine and Cardiology, Herlev and Gentofte Hospital, Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Steffan Svejgaard</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Novo Nordisk A/S, M&#xe5;l&#xf8;v, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fjordager</LastName><ForeName>Charlotte Gands&#xf8;</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Novo Nordisk A/S, M&#xe5;l&#xf8;v, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lauritsen</LastName><ForeName>Klara T&#xf8;lb&#xf8;ll</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Novo Nordisk A/S, M&#xe5;l&#xf8;v, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hilsted</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boding</LastName><ForeName>Lasse</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The National Biobank, Statens Serum Institut, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iversen</LastName><ForeName>Kasper Karmark</ForeName><Initials>KK</Initials><Identifier Source="ORCID">0000-0003-0504-8487</Identifier><AffiliationInfo><Affiliation>Department of Emergency Medicine and Cardiology, Herlev and Gentofte Hospital, Herlev, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyveled</LastName><ForeName>Liselotte</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Novo Nordisk A/S, S&#xf8;borg, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garred</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-2876-8586</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Medicine, Department of Clinical Immunology, Section 7631, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Intern Med</MedlineTA><NlmUniqueID>8904841</NlmUniqueID><ISSNLinking>0954-6820</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000092922" MajorTopicYN="N">Working Conditions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibody</Keyword><Keyword MajorTopicYN="N">infection</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">transmission</Keyword><Keyword MajorTopicYN="N">waning</Keyword><Keyword MajorTopicYN="N">working environment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>6</Day><Hour>21</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37024264</ArticleId><ArticleId IdType="doi">10.1111/joim.13637</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>WHO. Coronavirus disease 2019 (COVID-19) situation report-51. 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10.</Citation></Reference><Reference><Citation>WHO. 2020. Who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020. Available from: https://www.who.int/director-general/speeches/detail/.</Citation></Reference><Reference><Citation>The Danish Health Authority. Current data on the development of coronavirus. 2021. Available from: https://www.sst.dk/en/English/Corona-eng/Status-of-the-epidemic/COVID-19-updates-Statistics-and-charts.</Citation></Reference><Reference><Citation>Danske Regioner. The Danish COVID-19 vaccination programme. Available from: https://www.regioner.dk/sundhed/coronaviruscovid-19/vaccination-mod-covid-19/the-danish-covid-19-vaccination-programme.</Citation></Reference><Reference><Citation>Iversen K, Bundgaard H, Hasselbalch RB, Kristensen JH, Nielsen PB, Pries-Heje M, et&#xa0;al. Risk of COVID-19 in healthcare workers in Denmark: an observational cohort study. Lancet Infect Dis. 2020;20(12):1401-8.</Citation></Reference><Reference><Citation>Fogh K, Eriksen ARR, Hasselbalch RB, Kristensen ES, Bundgaard H, Nielsen SD, et&#xa0;al. Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark. BMC Infect Dis. 2022;22(1):143.</Citation></Reference><Reference><Citation>Zivich PN, Huang W, Walsh A, Dutta P, Eisenberg M, Aiello AE. Measuring office workplace interactions and hand hygiene behaviors through electronic sensors: a feasibility study. PLoS One. 2021;16(1):e0243358.</Citation></Reference><Reference><Citation>Nyberg A, Rajaleid K, Demmelmaier I. The work environment during coronavirus epidemics and pandemics: a systematic review of studies using quantitative, qualitative, and mixed-methods designs. Int J Environ Res Public Health. 2022;19(11):6783.</Citation></Reference><Reference><Citation>The Novo Group (Novo Nordisk). Available from: https://www.novonordisk.com/about/who-we-are.html.</Citation></Reference><Reference><Citation>Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-81.</Citation></Reference><Reference><Citation>Hansen CB, Jarlhelt I, P&#xe9;rez-Al&#xf3;s L, Landsy LH, Loftager M, Rosbjerg A, et&#xa0;al. SARS-CoV-2 antibody responses are correlated to disease severity in COVID-19 convalescent individuals. J Immunol. 2021;206(1):109-17.</Citation></Reference><Reference><Citation>P&#xe9;rez-Al&#xf3;s L, Armenteros JJA, Madsen JR, Hansen CB, Jarlhelt I, Hamm SR, et&#xa0;al. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. Nat Commun. 2022;13(1):1614.</Citation></Reference><Reference><Citation>Fogh K, Strange JE, Scharff BFSS, Eriksen ARR, Hasselbalch RB, Bundgaard H, et&#xa0;al. Testing Denmark: a Danish nationwide surveillance study of COVID-19. Microbiol Spectr. 2021;9(3):e0133021.</Citation></Reference><Reference><Citation>Espenhain L, Tribler S, J&#xf8;rgensen CS, Hansen CH, S&#xf6;nksen UW, Ethelberg S. Prevalence of SARS-CoV-2 antibodies in Denmark: nationwide, population-based seroepidemiological study. Eur J Epidemiol. 2021;36(7):715-25.</Citation></Reference><Reference><Citation>Erikstrup C, Hother CE, Pedersen OBV, M&#xf8;lbak K, Skov RL, Holm DK, et&#xa0;al. Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors. Clin Infect Dis. 2021;72(2):249-53.</Citation></Reference><Reference><Citation>The National COVID-19 Prevalence Study. Statens Serum Institut (SSI). Available from: https://covid19.ssi.dk/overvagningsdata/undersoegelser/praevalensundersogelsen.</Citation></Reference><Reference><Citation>Surveillance data for COVID-19 in Denmark and Europe. Statens Serum Institut (SSI). Available from: https://covid19.ssi.dk/overvagningsdata.</Citation></Reference><Reference><Citation>Lai CC, Wang JH, Hsueh PR. Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: an up-to-date review. Int J Infect Dis. 2020;101:314-22.</Citation></Reference><Reference><Citation>Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, et&#xa0;al. Global seroprevalence of SARS-CoV-2 antibodies: a systematic review and meta-analysis. PLoS One. 2021;16(6):e0252617.</Citation></Reference><Reference><Citation>Chen X, Chen Z, Azman AS, Deng X, Sun R, Zhao Z, et&#xa0;al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. Lancet Glob Health. 2021;9(5):e598-609.</Citation></Reference><Reference><Citation>Erikstrup C, S&#xf8;rensen E, Nielsen KR, Bruun MT, Petersen MS, Rostgaard K, et&#xa0;al. Cohort profile: the Danish blood donor study. Int J Epidemiol. 2022:dyac194.</Citation></Reference><Reference><Citation>Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M, Leeman D, et&#xa0;al. Antibody response to SARS-CoV-2 infection in humans: a systematic review. PLoS One. 2020;15(12):e0244126.</Citation></Reference><Reference><Citation>Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et&#xa0;al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020;5(52):eabe0367.</Citation></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et&#xa0;al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639-44.</Citation></Reference><Reference><Citation>Lau EH, Hui DS, Tsang OT, Chan W-H, Kwan MY, Chiu SS, et&#xa0;al. Long-term persistence of SARS-CoV-2 neutralising antibody responses after infection and estimates of the duration of protection. eClinicalMedicine. 2021;41:101174.</Citation></Reference><Reference><Citation>Harris RJ, Whitaker HJ, Andrews NJ, Aiano F, Amin-Chowdhury Z, Flood J, et&#xa0;al. Serological surveillance of SARS-CoV-2: six-month trends and antibody response in a cohort of public health workers. J Infect. 2021;82(5):162-9.</Citation></Reference><Reference><Citation>Forgacs D, Moraes VS, Hanley HB, Gattiker JL, Jefferson AM, Ross TM. The effect of waning on antibody levels and memory B cell recall following SARS-CoV-2 infection or vaccination. Vaccines (Basel). 2022;10(5):696. 2022.03.16.484099.</Citation></Reference><Reference><Citation>Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Ash N, et&#xa0;al. Protection and waning of natural and hybrid immunity to SARS-CoV-2. N Engl J Med. 2022;386(23):2201-12.</Citation></Reference><Reference><Citation>Hansen CB, Jarlhelt I, Hasselbalch RB, Hamm SR, Fogh K, Pries-Heje MM, et&#xa0;al. Antibody-dependent neutralising capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming. J Intern Med. 2021:290(6):1272-4.</Citation></Reference><Reference><Citation>To KK, Sridhar S, Chiu KH-Y, Hung DL-L, Li X, Hung IF-N, et&#xa0;al. Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerg Microbes Infect. 2021;10(1):507-35.</Citation></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et&#xa0;al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-32.</Citation></Reference><Reference><Citation>Petersen MS, Kristiansen MF, Hanusson KD, Danielsen ME, Steig B&#xc1;, Gaini S, et&#xa0;al. Long COVID in the faroe islands: a longitudinal study among nonhospitalized patients. Clin Infect Dis. 2021;73(11):e4058-63.</Citation></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et&#xa0;al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-31.</Citation></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et&#xa0;al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6(9):e005427.</Citation></Reference><Reference><Citation>Fogh K, Larsen TG, Hansen CB, Hasselbalch RB, Eriksen ARR, Bundgaard H, et&#xa0;al. Self-reported long COVID and its association with the presence of SARS-CoV-2 antibodies in a Danish cohort up to 12 months after infection. Microbiol Spectr. 2022;10(6):e0253722.</Citation></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long Covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648.</Citation></Reference><Reference><Citation>Talic S, Shah S, Wild H, Gasevic D, Maharaj A, Ademi Z, et&#xa0;al. Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and Covid-19 mortality: systematic review and meta-analysis. BMJ. 2021. 375:e068302.</Citation></Reference><Reference><Citation>Eriksen ARR, Fogh K, Hasselbalch RB, Bundgaard H, Nielsen SD, J&#xf8;rgensen CS, et&#xa0;al. SARS-CoV-2 antibody prevalence among homeless people and shelter workers in Denmark: a nationwide cross-sectional study. BMC Public Health. 2022;22(1):1261.</Citation></Reference><Reference><Citation>Madewell ZJ, Yang Y, Longini IM Jr, Halloran ME, Dean NE. Household transmission of SARS-CoV-2: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(12):e2031756.</Citation></Reference><Reference><Citation>Thompson HA, Mousa A, Dighe A, Fu H, Arnedo-Pena A, Barrett P, et&#xa0;al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) setting-specific transmission rates: a systematic review and meta-analysis. Clin Infect Dis. 2021;73(3):e754-64.</Citation></Reference><Reference><Citation>Lemieux JE, Siddle KJ, Shaw BM, Loreth C, Schaffner SF, Gladden-Young A, et&#xa0;al. Phylogenetic analysis of SARS-CoV-2 in Boston highlights the impact of superspreading events. Science. 2021;371(6529):eabe3261.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>